Creative Medical Technology Holdings closed at $0.61 on Nov 5, down 7.05%, within 0.0% of its 52-week closing low. Volume of 125.4K shares was 1.14× its 20-day average (close to normal).
Split-adjusted performance: -31.8% over one month, -73.5% over six months, -78.7% over one year.
Short interest was 82.1K shares at the Oct 15 settlement, down 50.2% from the prior report (1.3% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CELZCreative Medical Technology Holdings | $0.6059 | −7.05% | −73.5% | — | — | — | $4.6M | |
| PMCBPharmaCyte Biotech | $0.3752 | −1.52% | −53.1% | — | — | — | $4.0M | Compare |
| LIMNLiminatus Pharma | $2.63 | −5.88% | −73.8% | — | — | — | $3.5M | Compare |
| AIMAIM ImmunoTech | $0.1521 | −5.53% | −72.8% | +4.0% | −26876.9% | — | $6.1M | Compare |
| SNTISenti Biosciences Holdings | $0.1645 | −6.85% | −83.3% | — | −75000.0% | — | $6.3M | Compare |
| INABIN8bio | $0.8300 | −10.82% | −48.1% | — | — | — | $8.2M | Compare |
| HLSQTessera Defense and Homeland Security | $0.1241 | −13.82% | — | — | — | — | $2.6M | Compare |
| INTSIntensity Therapeutics | $3.10 | −11.43% | −39.3% | — | — | — | $10.1M | Compare |
| SLXNSilexion Therapeutics | $0.1438 | −6.32% | −97.2% | — | — | — | $2.1M | Compare |
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
